This raises the question of whether a PD-1 antibody targeting the T-cell surface has a more direct regulatory effect on the immune system compared to a PD-L1 antibody targeting the tumor cell surface, potentially leading to better treatment outcomes (17). Here, CD274 is linked to neoplasm.